



Innovating for
affordable healthcare

Shilpa Medicare Limited

Manufacturers and Exporters of Bulk Drugs

10/80, Rajendra Gunj, RAICHUR - 584 102. (INDIA)

Phone : +91-8532-235006, 235704 Fax : +91-8532-235876

E-mail : info@vbshilpa.com, Website : www.vbshilpa.com

CIN No. L85110KA1987PLC008739

SML/701/2015-16

Date: 07.08.2015

To,
The Corporate Relationship Department
National Stock Exchange of India Limited,
Exchange Plaza, Plot No/C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051.

Dear Sir's,

Sub: Submission of UFR and Auditor's Report for the Quarter Ended 30th June, 2015

Ref: Stock Symbol: NSE - SHILPAMED

With respect to the subject cited above, we herewith forward the standalone and consolidated Un-audited financial results for the quarter ended 30th June, 2015, along with the Auditor's Report, as per clause 41 of the Listing Agreement.

This is for your information & records.

Thanking you,

Yours faithfully,

For **SHILPA MEDICARE LIMITED**

**RAMAKANT INNANI
AUTHORISED SIGNATORY**

Encl:a.a



SHILPA MEDICARE LIMITED

Regd. Office: # 10/80, First Floor, Rajendra Gunj, Raichur-584102(Karnataka)
UNAUDITED FINANCIAL RESULTS FOR 1ST QUARTER ENDED 30TH JUNE-2015

PART-I

(Rs. In Lacs)

Particulars	Quarter Ended						Year Ended	
	Standalone			Consolidated			Standalone	Consolidated
	Unaudited 30.06.15	Audited 31.03.15	Unaudited 30.06.14	Unaudited 30.06.15	Audited 31.03.15	Unaudited 30.06.14	Audited 31.03.15	Audited 31.03.15
1 Income from operations								
(a) Net sales/income from operations (Net of Excise Duty)	14385.67	15010.32	12672.59	14850.48	16673.27	13890.19	56540.21	61379.91
Total income from operations (net)	14385.67	15010.32	12672.59	14850.48	16673.27	13890.19	56540.21	61379.91
2 Expenses								
(a) Cost of materials consumed	10209.79	6525.07	6230.73	10324.65	6817.47	6595.03	30786.61	31902.43
(b) Purchases of stock-in-trade	28.74	209.81	101.07	28.74	209.81	101.07	606.83	606.83
(c) Changes in inventories of finished goods, WIP, Stock	(2,290.81)	656.83	958.13	(2,350.48)	967.51	845.79	(311.15)	(39.38)
(d) Employee benefits expense	1506.49	1869.78	1176.55	2068.88	2479.40	1855.41	5648.85	8230.11
(e) Depreciation and amortisation expense	484.45	483.49	494.61	532.53	540.61	552.63	1908.50	2141.17
(f) Other expenses	1660.78	1896.93	1135.00	1955.39	2421.73	1541.73	6156.29	7816.38
Total Expense	11599.44	11641.92	10096.09	12559.71	13436.54	11491.66	44795.93	50657.54
3 Profit/(Loss) from Operations before Other Income, Finance Costs & exceptional items (1-2)	2786.23	3368.40	2576.50	2290.77	3236.73	2398.53	11744.28	10722.37
4 Other Income	75.72	109.40	145.99	18.49	80.33	101.30	545.34	479.89
5 Profit/(Loss) from Ordinary activities before finance cost & exceptional items (3+/-4)	2861.95	3477.80	2722.49	2309.26	3317.07	2499.83	12289.62	11202.26
6 Finance costs	80.75	91.61	95.76	82.02	95.45	100.85	387.98	405.02
7 Profit/(Loss) from ordinary activities after finance cost but before exceptional items (5 +/- 6)	2781.20	3386.19	2626.73	2227.24	3221.61	2398.98	11901.64	10797.24
8 Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9 Profit/(Loss) from Ordinary Activities before tax (7 +/- 8)	2781.20	3386.19	2626.73	2227.24	3221.61	2398.98	11901.64	10797.24
10 Tax expense	653.20	1031.96	723.24	651.03	1026.58	720.42	3483.53	3521.58
11 Net Profit/(Loss) from ordinary activities after tax (9 +/- 10)	2128.00	2354.23	1903.49	1576.21	2195.03	1678.56	8418.11	7275.66
12 Extraordinary Items Income / (Expenses)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(4.83)
13 Net Profit/(Loss) for the period (11+12)	2128.00	2354.23	1903.49	1576.21	2195.03	1678.56	8418.11	7270.82
14 Share of Profit / (Loss) of associates	-	-	-	-	-	-	-	-
15 Add: (Gain) / loss pertaining to Minority Interest	-	-	-	29.71	52.38	28.71	-	106.65
16 Net Profit / (loss) after taxes, minority interest and share of profit/(loss) of associates (13+/-14+/-15)	2128.00	2354.23	1903.49	1605.92	2247.41	1707.27	8418.11	7377.47
17 Paid-up equity share capital (Face value of Rs 2/-)	771.02	771.02	771.02	771.02	771.02	771.02	771.02	771.02
18 Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	-	55538.56	53923.10
19 Earnings Per Share (EPS) (before extraordinary items) (of Rs.2/- each) (not annualized):								
a) Basic	5.52	6.14	5.05	4.17	5.86	4.53	21.94	19.23
b) Diluted	5.52	6.14	5.05	4.17	5.86	4.53	21.94	19.23
19.i Earnings Per Share (EPS) (after extraordinary items) (of Rs.2/- each) (not annualized):								
a) Basic	5.52	6.14	5.05	4.17	5.86	4.53	21.94	19.22
b) Diluted	5.52	6.14	5.05	4.17	5.86	4.53	21.94	19.22

PART-II								
A. PARTICULARS OF SHARE HOLDING								
1	Public Shareholding	18097294	18097294	17994294	18097294	18097294	17994294	18097294
	- Number of Shares							
	- Percentage of shareholding	46.94	46.94	46.68	46.94	46.94	46.68	46.94
2	Promoters & Promoters group Shareholding							
	a) Pledged / Encumbered							
	- Number of shares	-	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share of promoter and promoter group)	-	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-	-
	b) Non encumbered							
	- Number of shares	20453658	20453658	20556658	20453658	20453658	20556658	20453658
	Percentage of shares (as a % of the total share holding of promoter and promoter group)	100	100	100	100	100	100	100
	- Percentage of shares (as a % of the total share capital of the Company)	53.06	53.06	53.32	53.06	53.06	53.32	53.06
B PARTICULARS OF INVESTOR COMPLAINTS								
Particulars		Three Months ended 30th June,2015						
Pending at the beginning of the quarter		Nil						
Received during the quarter		23						
Disposed off during the quarter		23						
Remaining unresolved at the end of the quarter		Nil						

Notes:

- 1 Unaudited Financial Results have been reviewed by the Audit Committee and approved at the meeting of the Board of Directors.
- 2 Figures of the previous year/quarter have been regrouped/rearranged wherever necessary.
- 3 Tax Expenses includes Current Tax & Deferred Tax.
- 4 "During the Quarter Company's Share in Maia Pharmaceuticals Inc , a joint venture entity, has come down from 49.801% to 34.792%.
- 5 Figure for the quarter ended March 31,2015 are the balancing figure between audited figure for the year ended March 31,2015 and year to date figure upto third ended December 31,2014.
- 6 As per As-17 reportable segment is only one i.e. Bulk Drug & API, therefore segment reporting is not applicable.

Place:Hyderabad
Date:07/8/2015

By the order of the Board of Directors
for SHILPA MEDICARE LIMITED


Chairman